Danbiosyst UK Limited

West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited

Other

University of Nottingham

Chiron Corporation

Knoll Aktiengesellschaft

Forest Laboratories, Inc.

Isc Chemicals Limited

University of Gent

Stanley Stewart Davis

Paolo Ferruti

Wu Lin

Fabio Bignotti

Allan Gerald Coombes

Lisbeth Illum

Martin Charles Garnett

Moein Moghimi

Clive Washington

Derek T O'Hagen

Nicola Christy

Norman G Gaylord

Peter James Watts

Etienne Honore Schacht

David E Wotton

Ming-Kung Yeh

Karin Schaupp

Josef Polzer

Kurt Lanthaler

Andrew Wells

Johannes Kerbl

John Michael Wood

Allan G A Coombes

Diane Lisa Major

Fiona Caroline Maclaughlin

Paul George Jenkins

Alan Gerald Coombes

PEG-chitosan conjugates comprising chitosan and polyethylene glycol moieties or derivatives thereof which are bonded together and their use in medicine is described. In one embodiment, the conjugate comprises a chitosan moiety or a derivative thereof and a polyethylene glycol moiety or a derivative thereof which are bonded together via the amino function on the chitosan by the use of an activated chitosan species. In another embodiment, the conjugate comprises a chitosan moiety or a derivative thereof and a polyethylene glycol moiety or a derivative thereof which are bonded together, the chitosan portion of the conjugate having a molecular weight in the range of from 10 kilodaltons to 1000 kilodaltons.

Conjugate of polyethylene glycol and chitosan

A process for attaching a polyethylene glycol compound to a macromolecule to prepare a conjugate or adduct between the polyethylene glycol compound and the macromolecule is described. The process comprises the steps of (1) preparing an activated PEG or an activated PEG derivative by incorporating an acrylic ester, an acrylic thioester or an acrylamido group into the PEG or PEG derivative; (2) reacting the activated PEG or PEG derivative with a macromolecular material comprising one or more sulphydryl groups, primary amino groups and/or secondary amino groups and (3) recovering the conjugate of the PEG or PEG derivative and the macromolecular material.

Method for attaching polyethylene glycol to macromolecules

Lamellar particles are provided comprising a biodegradable and biocompatible polymer and carrying a cationic charge on their surface. These particles are prepared by mixing a preformed negatively charged lamellar particle with a positively charged material. Compositions using these particles may include genetic material or antigens, for example, and may be used as a drug delivery system, such as a sustained release system.

Surface modification of lamellar particles

A process is described for preparing microspheres, films and coatings from protein or modified protein in which the protein product is stabilized by carrying out the preparation in the presence of an aqueous solution of at least one &agr;-hydroxy acid. The microspheres, films and coatings so produced have improved stability in aqueous solution.

Preparation of protein microspheres, films and coatings

A composition for delivering a biologically active polyanionic molecule comprising a linear polymer with a backbone comprising amido and tertiary amino groups arranged regularly on the backbone and biologically active polyanionic molecule bound to the polymer. Preferably, the linear polymer comprises a poly(amidoamine). Preferably, the biologically active polyanionic molecule is a nucleic acid, more preferably a DNA. The compositions are useful for delivering nucleic acids to a cell in a cell transformation, transfection or gene therapy method.

Polymer composition for delivering a nucleic acid or derivative thereof

There is provided a composition for the nasal delivery of a cannabinoid which comprises a cannabinoid in a biphasic delivery system or a cannabinoid in a microsphere delivery system.

Compositions comprising cannabinoids

Polymeric lamellar substrate particles for drug delivery

A composition for delivering an active agent to the lymphatic system comprises a plurality of colloidal particles and an active agent associated with each particle, wherein the surface of each particle has a hudrophobicity ratio as defined of less than 10, or wherein a modifying agent is adsorbed onto the surface of each particle such that the modifying agent gives an advancing contact angle as defined of less than 60.degree. or wherein the adsorbed layer thickness as defined is less than 10 nm or the albumin uptake ratio is between 0.2 and 0.5. The composition may satisfy one or more of these requirements. Preferred modifying agents are non-ionic surfactants, in particular block copolymers containing polyethyleneglycol.

Lymphatic delivery methods

Polymer microspheres and a method of production thereof

Polymer microparticles for drug delivery

Lymphatic delivery composition

A stable active substance emulsion of the oil-in-water type with a phospholipid as emulsifier is described, where the active substance dissolved in the lipid phase has one or more basic groups, is hydrophobic and oil-soluble, and has a pKa of at least 7.5, the aqueous phase is set at an acid pH, and the disperse phase gives a positive zeta potential of at least +15, but preferably +30, mV after dilution of the emulsion ready for administration to a fat content of 0.08% by weight.

Stable emulsion suitable for pharmaceutical administration, the

Preparation of oil-in-water emulsions of drugs

Increased stability is conferred on oil-in-water emulsions of perfluorocarbons by addition of a minor (0.1-5% w/v) amount of a fluorinated compound of higher boiling point than the perfluorocarbon being emulsified. The added fluorinated compound is preferably a perfluorinated saturated polycyclic hydrocarbon. The most preferred additive is perfluoroperhydrofluoranthene.

Emulsions of perfluorocarbons in aqueous media

Growing community of inventors

Nottingham, United Kingdom

Stanley Stewart Davis